ETON PHARMACEUTICALS INC (ETON)

Company Profile

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 28 full-time employees. The company went IPO on 2018-11-09. The company has three commercial rare disease products, ALKINDI SPRINKLE for the treatment of adrenocortical insufficiency, Carglumic Acid for the treatment of hyperammonemia due to N-acetylglutamate synthase deficiency, and Betaine Anhydrous for the treatment of homocystinuria. The company also has three additional product candidates in late-stage development. The firm is developing dehydrated alcohol injection, which has received Orphan Drug Designation for the treatment of methanol poisoning, ZENEO hydrocortisone autoinjector for the treatment of adrenal crisis, and ET-400. Its dehydrated alcohol injection product candidate is under review for the treatment of methanol poisoning. Its ZENEO hydrocortisone autoinjector product candidate is a needle-free autoinjector under development for the treatment of adrenal crisis.

Company Info

ETON PHARMACEUTICALS INC

21925 W Field Pkwy Ste 235

Deer Park ILLINOIS 60010

P: 18477877361

CEO: Sean E. Brynjelsen

Employees: 28

Website: https://etonpharma.com/